Ixekizumab is a humanized monoclonal antibody that specifically inhibits IL-17A. It has been approved for the treatment of adult and pediatric psoriasis, psoriatic arthritis and axial spondyloarthropathies by the US FDA and the EMA. Phase III trials, post hoc analyses and real-life data have reported its efficacy, effectiveness and safety. This review summarizes the latest evidence on the clinical efficacy, pharmacology and safety profile of ixekizumab for the treatment of moderate-to-severe psoriasis. A literature search was performed for articles published through December 2022. Ixekizumab is one of the most efficacious biologics for psoriasis, with a rapid onset of response, favorable long-term outcomes and an adequate safety profile.
Keywords: IL-17A; dermatology; efficacy; ixekizumab; pharmacology; psoriasis; safety.
Ixekizumab is a biologic therapy, a type of disease treatment that uses substances from living organisms, currently available for the treatment of psoriasis. It works as an antibody directed against a molecule that causes inflammation, named IL-17A, which is essential for the development of psoriasis lesions. Ixekizumab has been approved by the US FDA and EMA for the treatment of psoriasis, psoriatic arthritis and axial spondyloarthropathies in adults and children. Its effectiveness and safety have been widely proven in multiple clinical trials and real-life settings. This review summarizes the latest evidence on the clinical efficacy, pharmacology and safety profile of ixekizumab for the treatment of moderate-to-severe psoriasis.